Copyright © 1999 by Institute of Pharmacology
Polish Academy of Sciences 		Pol. J. Pharmacol., 1999, 51, 455-462
ISSN 1230-6002
Go to: Contents | Next Article | PJP - Home Page |


REVIEW
 ANGIOGENESIS INHIBITORS. NEW ANTICANCER STRATEGY
 Witold Zgodziński#, Grzegorz Wallner, Andrzej D¹browski
 2nd Department of General Surgery, University School of Medicine in Lublin, Staszica 16, PL 20-081 Lublin, Poland

Angiogenesis inhibitors. New anticancer strategy. W. ZGODZIŃSKI, G. WALLNER, A. D„BROWSKI. Pol. J. Pharmacol., 1999, 51, 455-462.

Neoangiogenesis has been proved to be crucial in neoplasmatic tumor growth and metastases. Over the last few years, the factors that have both a positive (angiogenic) and negative (antiangiogenic) influence on tumor growth have been identified. The potential use of natural and synthetic factors that suppress vasculature formation as anticancer drugs is currently under intense investigation. Recently, several antiangiogenic compounds, including TNP-470 or matrix metalloproteinase inhibitors, have entered clinical trials. This review will describe the main groups of angiogenesis inhibitors, their mechanisms of action and some data from clinical studies.

Key words: angiogenesis inhibitors, neoangiogenesis, neoplasmatic tumors
  # correspondence
Back to: Top | PJP - Home Page |